Adicet Bio, Inc. (ACET) financial statements (2022 and earlier)

Company profile

Business Address 200 CLARENDON STREET
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:277,544 91,5007,042
Cash and cash equivalents277,544 33,7747,042
Other undisclosed cash, cash equivalents, and short-term investments  57,726 
Receivables214   
Prepaid expense1,021 1,7071,491
Other current assets2 7315
Other undisclosed current assets3,657 (27)100,986
Total current assets:282,438 93,253109,534
Noncurrent Assets
Operating lease, right-of-use asset20,358  
Property, plant and equipment14,643 414321
Intangible assets, net (including goodwill)19,462   
Goodwill19,462   
Restricted cash and investments150 24584
Other noncurrent assets1,887   
Total noncurrent assets:56,500 659405
TOTAL ASSETS:338,938 93,912109,939
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,786 12,1995,716
Accounts payable3,263 6,7162,989
Accrued liabilities503 5,4832,727
Employee-related liabilities4,020   
Deferred revenue4,805  
Other undisclosed current liabilities3,726   
Total current liabilities:16,317 12,1995,716
Noncurrent Liabilities
Long-term debt and lease obligation19,377   
Operating lease, liability19,377  
Liabilities, other than long-term debt  1519
Other liabilities  1519
Other undisclosed noncurrent liabilities(19,262)   
Total noncurrent liabilities:19,492 1519
Total liabilities:35,809 12,2145,735
Stockholders' equity
Stockholders' equity attributable to parent303,129 81,698104,204
Common stock4 43
Additional paid in capital471,449 235,777175,635
Accumulated other comprehensive income (loss)  49(41)
Accumulated deficit(168,324) (154,132)(71,393)
Total stockholders' equity:303,129 81,698104,204
TOTAL LIABILITIES AND EQUITY:338,938 93,912109,939

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues
(Revenue from Related Parties)
9,730   
Gross profit:9,730   
Operating expenses(71,163) (85,457)(39,705)
Operating loss:(61,433) (85,457)(39,705)
Nonoperating income (expense)(606) 2,7542,117
Investment income, nonoperating  2,817 
Other nonoperating income (expense)(606) (63)2,117
Interest and debt expense(176)   
Loss from continuing operations before equity method investments, income taxes:(62,215) (82,703)(37,588)
Other undisclosed income from continuing operations before income taxes91   
Loss from continuing operations before income taxes:(62,124) (82,703)(37,588)
Income tax expense (benefit)125 (36)(26)
Net loss available to common stockholders, diluted:(61,999) (82,739)(37,614)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(61,999) (82,739)(37,614)
Other comprehensive loss(24)   
Comprehensive loss:(62,023) (82,739)(37,614)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  90(41)
Comprehensive loss, net of tax, attributable to parent:(62,023) (82,649)(37,655)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: